Pfizer Inc. / Vivet Therapeutics S.A.S.

Wilson Disease

Disease Overview

Wilson disease is a rare autosomal-recessive disorder caused by mutations in the ATP7B gene, disabling normal copper biliary excretion and causing toxic copper accumulation in the liver, brain, and eyes. Untreated, it progresses to cirrhosis, neurologic deterioration, and death; current management requires lifelong copper chelation (penicillamine, trientine) or zinc therapy, with liver transplant the only curative option for advanced disease.

Competitive Landscape

Wilson disease therapy has historically relied on chronic copper chelators—Syprine (trientine), Cuprimine (penicillamine), and Galzin (zinc acetate)—which require strict daily adherence and carry meaningful tolerability burden. Alexion's WTX101 (bis-choline tetrathiomolybdate, later branded Cuvrior approval 2022 by Orphalan) and Orphalan's trientine tetrahydrochloride represented incremental improvements in tolerability but did not address the underlying ATP7B defect. Vivet's VTX-801 is an AAV-based gene therapy delivering a functional truncated ATP7B gene to hepatocytes, positioning it as the first potentially curative one-time therapy for Wilson disease. Pfizer's $635M option deal extends its rare-disease/AAV gene therapy franchise (alongside its hemophilia and Duchenne programs) and complements its rare-disease portfolio anchored by tafamidis. The deal validates Wilson disease as a precision-medicine target where a small but defined patient population (~11,000 in the US) commands orphan-drug economics, and shifts the competitive frame from chronic management to durable genetic correction. Source: https://www.pharmaceutical-technology.com/news/pfizer-buys-vivet-therapeutics-stake/